Subpar management & training of associates, self-centred trainers a normThe good thingsCandidly speaking, Novartis looks good on paper which in fact, it is plagued by numerous cost and spending issues and it is currently swimming in its own poo. Its outlook is also affected due to product divestment such as Parlodel etc, full testing becoming reduced testing etc.
The challengesI was asked to leave due to business needs. I was told the leave would be encashed at first, and in the next month, I was told that only half of my balance leave would be encashed and in the following month I was due to leave, I was told that none of the leave can be encashed. Understandably for cost savings. It is honestly a harsh and terribly unfriendly cut-throat place to work in. With its product divestment strategies and steep cost savings by decommissioning some of its equipment like balances and other new equipment, even going as far as to closing down 1 of the Labs in Novartis S'pore Pharm Manufacturing (Solids) and its massive reduction in spending in consumables and maintenance, its outlook for employees is not too promising and rosy after all.